Xenon Pharmaceuticals Inc. (XENE)
XENE Stock Price Chart
Explore Xenon Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze XENE price movements and trends.
XENE Company Profile
Discover essential business fundamentals and corporate details for Xenon Pharmaceuticals Inc. (XENE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Nov 2014
Employees
316.00
Website
https://www.xenon-pharma.comCEO
Andrea DiFabio
Description
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
XENE Financial Timeline
Browse a chronological timeline of Xenon Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$1.16, while revenue estimate is $1.67m.
Earnings released on 7 May 2026
EPS came in at -$1.17 matching the estimated -$1.17.
Earnings released on 26 Feb 2026
EPS came in at -$1.31 falling short of the estimated -$1.20 by -9.17%.
Earnings released on 3 Nov 2025
EPS came in at -$1.15 surpassing the estimated -$1.16 by +0.86%.
Earnings released on 11 Aug 2025
EPS came in at -$1.07 falling short of the estimated -$1.03 by -3.88%.
Earnings released on 12 May 2025
EPS came in at -$0.83 surpassing the estimated -$0.94 by +11.70%, while revenue for the quarter reached $7.50m , beating expectations by +293.44%.
Earnings released on 27 Feb 2025
EPS came in at -$0.84 surpassing the estimated -$0.89 by +5.62%.
Earnings released on 12 Nov 2024
EPS came in at -$0.81 surpassing the estimated -$0.82 by +0.69%.
Earnings released on 8 Aug 2024
EPS came in at -$0.75 falling short of the estimated -$0.72 by -4.17%.
Earnings released on 9 May 2024
EPS came in at -$0.62 surpassing the estimated -$0.69 by +10.14%.
Earnings released on 29 Feb 2024
EPS came in at -$0.64 surpassing the estimated -$0.76 by +15.79%, while revenue for the quarter reached $5.38m , beating expectations by +184.66%.
Earnings released on 8 Nov 2023
EPS came in at -$0.73 surpassing the estimated -$0.75 by +2.67%.
Earnings released on 9 Aug 2023
EPS came in at -$0.72 falling short of the estimated -$0.69 by -4.35%.
Earnings released on 9 May 2023
EPS came in at -$0.63 falling short of the estimated -$0.62 by -1.61%.
Earnings released on 1 Mar 2023
EPS came in at -$0.57 surpassing the estimated -$0.58 by +1.72%, while revenue for the quarter reached $8.77k , missing expectations by -99.70%.
Earnings released on 8 Nov 2022
EPS came in at -$0.57 falling short of the estimated -$0.52 by -9.62%, while revenue for the quarter reached $132.00k , missing expectations by -96.82%.
Earnings released on 9 Aug 2022
EPS came in at -$0.55 falling short of the estimated -$0.49 by -12.24%, while revenue for the quarter reached $536.00k , missing expectations by -87.17%.
Earnings released on 10 May 2022
EPS came in at -$0.35 surpassing the estimated -$0.38 by +7.89%, while revenue for the quarter reached $8.77m , beating expectations by +13.29%.
Earnings released on 1 Mar 2022
EPS came in at -$0.57 falling short of the estimated -$0.47 by -21.28%, while revenue for the quarter reached $3.74m , missing expectations by -34.27%.
Earnings released on 10 Nov 2021
EPS came in at -$0.36 surpassing the estimated -$0.44 by +18.18%, while revenue for the quarter reached $8.12m , missing expectations by -15.38%.
Earnings released on 11 Aug 2021
EPS came in at -$0.51 falling short of the estimated -$0.49 by -4.08%, while revenue for the quarter reached $2.22m , meeting expectations.
XENE Stock Performance
Access detailed XENE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
